chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Dose of Pneumovax 3 given in AM. Within 8 hours developed pain, swelling, increased warmth around injection site. Within 12 hours developed fever. Applied ice and took Motrin. Within 48 hours symptoms resolving but slight pain and swelling persist.
Administered an expired dose; This case was reported by a nurse via call center representative and described the occurrence of expired vaccine used in a 23-year-old male patient who received HAV (Havrix) (batch number 3A22R, expiry date 24th May 2022) for prophylaxis.   On 8th June 2022, the patient received the 3rd dose of Havrix. On 8th June 2022, unknown after receiving Havrix, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.       Additional Information: GSK Receipt Date: 08-JUN-2022 Reporter's Comment: The reporter reported that, a patient was administered an expired dose of the Havrix vaccine in right deltoid. The reporter consented to follow up. Additional Supportive Information: The patient was administered an expired dose of the Havrix vaccine, which led to expired vaccine used.
Less fever but chills; Swollen lymph node above clavicle/supraclavicle lymph node; Painful lymph node above my clavicle/ painful supraclavicle lymph node; Certainly arm and shoulder pain; Shoulder pain; This case was reported by a consumer via call center representative and described the occurrence of chills in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On 11th October 2021, the patient received Shingrix. In October 2021, less than a week after receiving Shingrix, the patient experienced chills, supraclavicular lymph nodes enlarged, lymph node pain, pain in arm and shoulder pain. On an unknown date, the outcome of the chills, supraclavicular lymph nodes enlarged, lymph node pain, pain in arm and shoulder pain were unknown.   It was unknown if the reporter considered the chills, supraclavicular lymph nodes enlarged, lymph node pain, pain in arm and shoulder pain to be related to Shingrix.  Additional details were provided as follows: The reporter was the patient. The age at vaccination was not reported. The patient got the Shingrix vaccine on Monday before the reporting date and had all the symptoms above (other symptoms) less fever but had chills. Moreover, the patient also developed a swollen, painful lymph node above his/her clavicle, certainly arm and shoulder pain. The patient developed painful supraclavicle lymph node and was asking if he/she was okay and was that normal to happen. The reporter wished that he/she could send a photo of the same.
Pt. experienced arm soreness for about 2 days post vaccination. No pain to report for 2 weeks, then pain in vaccinated area started along with 3, pea sized lumps. Lumps are tender & arm is tender
sore arm; sick; sometimes they work but not very often; Initial information received on 18-Dec-2021 regarding an unsolicited valid Social Media non-serious case received from a consumer/non-hcp.  This case involves Adult and unknown gender patient who experienced sore arm, sick and sometimes they work but not very often, while receiving vaccine INFLUENZA VACCINE.     The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.    On an unknown date, the patient received a  dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported (formulation, dose, route unknown).  On an unknown date the patient developed a non-serious sore arm (pain in extremity) (unknown latency) following the administration of INFLUENZA VACCINE. On an unknown date the patient developed a non-serious sick (illness) (unknown latency) following the administration of INFLUENZA VACCINE. On an unknown date the patient developed a non-serious event, "sometimes they work but not very often" (therapeutic response decreased) (unknown latency) following the administration of INFLUENZA VACCINE.  It was reported, "I've had several years of flu shots sometimes they work but not very often. but they always give me a sore arm and make me have sick for a half a day. A total crapshoot."  Action taken with INFLUENZA VACCINE (INFLUENZA VACCINE) was not applicable.  It was not reported if the patient received a corrective treatment for the events (sometimes they work but not very often, sore arm, sick).  At time of reporting, the outcome was Unknown for the event sometimes they work but not very often, was Unknown for the event sore arm and was Unknown for the event sick.
Patient states that after receiving the 1st dose of Shingrix 01/12/2022, started experiencing symptoms that evening of fever, chills, nausea, abdominal pain, fatigue, and muscle aches. No noted Primary visit/communications. Pt. still experiencing symptoms.
About 1 day following the injection my husband complained of vertigo or a general feeling of instability. This was disturbing for 2 or 3 days and slowly subsided until it was no longer noticeable by about Wednesday, 3/17/2021. No other side effects were experienced.
Pain in the injection site on left arm; dizziness; fatigue; back pain; This is a spontaneous report from a contactable consumer (patient). A 38-year-old male patient received second dose of bnt162b2 (lot number: 3247), via an unspecified route of administration, at arm left, on 16Feb2021 09:45 at single dose for COVID-19 immunisation. The patient medical history was not reported. No allergies to medications, food, or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. Concomitant medication included fluticasone propionate (FLONASE) within 2 weeks of vaccination. Historical vaccine included first dose of bnt162b2 (lot number: 3247) at left arm on 26Jan2021 09:45 at 38-year-old for COVID-19 immunization. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient experienced Pain in the injection site on left arm; dizziness the next morning; fatigue; back pain on 17Feb2021. No treatment received for the adverse event. The case was reported as not serious.  The outcome of the events were not recovered.  No follow-up attempts are possible. No further information is expected.
Has a squeezing and turning sensation like a tight burn from her ankles to her knees; Bruising on her feet that went up her legs and on her wrists up her arms; Swelling to her feet up to her legs, arms and hands; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 29 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 30Jul2021 17:30 (Lot number: FA6780) at the age of 29 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PERIPHERAL SWELLING (non-serious) with onset 09Aug2021, outcome "recovering", described as "Swelling to her feet up to her legs, arms and hands"; CONTUSION (non-serious) with onset 10Aug2021, outcome "not recovered", described as "Bruising on her feet that went up her legs and on her wrists up her arms"; BURNING SENSATION (non-serious) with onset 11Aug2021, outcome "not recovered", described as "Has a squeezing and turning sensation like a tight burn from her ankles to her knees". The events "swelling to her feet up to her legs, arms and hands", "bruising on her feet that went up her legs and on her wrists up her arms" and "has a squeezing and turning sensation like a tight burn from her ankles to her knees" were evaluated at the emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: The patient did not receive any other vaccinations within four weeks prior to the first administration date of the suspect vaccine. The patient had no AE(s) following prior vaccinations. It was reported that bruising started on feet, going up legs, on wrists to arms looks like petechiae, spreading and turning brown in the evening. The patient reported that it was worsened. Squeezing and turning sensation, Indian burn, tight burn, specific to ankles and knees started early evening. Caller stated that she went to the emergency room.  No follow-up attempts are possible. No further information is expected.
Patient presented 10 minutes after receiving the Pfizer COVID vaccine saying her throat was beginning to swell. I gave her 3 tbsp of oral liquid Benadryl (12.5mg/5mL) and observed her. After 10 minutes when patient said he throat felt even worse, I called the paramedics. They arrived 10 to 15 minutes later and checked her vital signs, which were all normal. They verified with her that she did not want to got to the hospital and said she was cleared. I asked her to stay a few more minutes and let me know how she felt before she left. She stayed in the waiting area for another 10 minutes and said she felt better before leaving.
Narrative: Syringe was drawn up from the vial on 6/1, 0.5 ml. It was not utilized or disposed of on 6/1 as would be appropriate for a 12 hour BUD. Since it was not disposed of per procedure and left in the vaccine prep area, the 6/2 staff did not note the 6/1 date and utilized this syringe to split and make two 0.25 ml booster vaccine doses. These were administered. No adverse outcome identified.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A female patient (not pregnant) received BNT162b2 (BNT162B2), on 24Feb2021 at 13:00 as dose 1, single (Batch/Lot number: unknown), in right arm, on 17Mar2021 at 10:00 as dose 2, single (Batch/Lot number: unknown), in left arm and on 18Oct2021 at 13:00 as dose 3 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Eczema" (unspecified if ongoing); "Osteoporosis" (unspecified if ongoing); "Herniated discs" (unspecified if ongoing); "Known Allergies: Oysters" (unspecified if ongoing), notes: Known Allergies: Oysters; "Known Allergies: Scallops" (unspecified if ongoing), notes: Known Allergies: Scallops; "Known Allergies: latex" (unspecified if ongoing); "Known Allergies: Sulfa drugs" (unspecified if ongoing), notes: Known Allergies: Sulfa drugs. Concomitant medication(s) included: VITAMIN D [COLECALCIFEROL], start date: Jan2022, stop date: 07May2022; PRESERVISION, start date: Feb2022, stop date: May2022. The following information was reported: COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant) all with onset 2022, outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Negative, notes: on day four and all better by day 7 with a negative. antigen test day 7; Positive, notes: day 10 from initial onset of symptoms and the first positive test. Therapeutic measures were taken as a result of covid-19, drug ineffective.  Additional information: Were you/Was the patient taking any other medications/products within 2 weeks of starting COVID-19 treatment?: Yes Did you/the patient previously receive a COVID-19 Vaccine?: Yes Reported Event: Had a metallic bitter taste in mouth for five days but felt better on day four and all better by day 7 with a negative antigen test day 7 and day 10 from initial onset of symptoms and the first positive test, but on day 13 started to have a lot of congestion, sneezing, headache, body aches, cough and fatigue. that lasted another 7 days getting somewhat better by day 18. Some aches and post nasal drip cough still occurring on day 21. Date of start of reaction/event: 01May2022 (12:00AM) Outcome of reaction/event at the time of last observation: Recovering/resolving Hospitalization Prolonged : No AE resulted in :None of the above Device Date : 07May2022.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Immediately following administration of MENACTRA in left deltoid and VARIVAX in upper left arm involuntary twitching of left arm. Patient very anxious and scared. Deep breathing and relaxation encouraged. Twitching lasted approximately 3 minutes.
Vomiting/ just threw up; This spontaneous case was reported by a consumer and describes the occurrence of VOMITING (Vomiting/ just threw up) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Diabetes.    On 28-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Aug-2021, the patient experienced VOMITING (Vomiting/ just threw up). At the time of the report, VOMITING (Vomiting/ just threw up) outcome was unknown.            Relevant concomitant medications were not provided. Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 31-Aug-2021: non significant follow up appended
headache; sore arm; he could no longer sleep; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  An adult male patient received bnt162b2 (BNT162B2), administration date 06Dec2021 09:30 (Batch/Lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose number: 2, Lot number: Unknown, reason: Not available/provided to reporter at the time of report completion), administration date: Feb2021, for Covid-19 Immunization; Bnt162b2 (Dose number: 1, Lot number: Unknown, reason: Not available/provided to reporter at the time of report completion), administration date: Jan2021, for COVID-19 Immunization. The following information was reported: HEADACHE (non-serious) with onset 07Dec2021, outcome "recovering", described as "headache"; PAIN IN EXTREMITY (non-serious) with onset 07Dec2021, outcome "recovering", described as "sore arm"; INSOMNIA (non-serious) with onset 07Dec2021, outcome "recovering", described as "he could no longer sleep". It was unknown if therapeutic measures were taken as a result of headache, pain in extremity, insomnia.  Additional information included: It was reported that lot number was not available or not provided by the reporter at the time of report completion. It was unknown if patient had received any other vaccine in four weeks. It was unknown if patient received treatment. It was unknown if patient had COVID prior vaccination. It was unknown if patient tested COVID post vaccination.  Follow-up are completed. Information about lot/batch number cannot be obtained. No further information is expected.
March 29: Right side of face swelling next day both sides of face and lymph nodes. Face, arm, chest, lower back; raised itchy rash. General malaise, aches, pain. Resolved 4/2/12. Residual rash, swelling. Rx: Cephalexin 500mg 3xday 7 days, Loratadine 10mg qd x 30 days, Triamcinolone 0.1% cream affected area 2x day.
Within 30 minutes she started feeling bad, coughing, congested, sore throat, body aches, headache, rash up both arms and across chest. NO Fever. Lasting from 2:30 Thursday November 12 until Friday evening November 13, 2009. Urgent care gave augmentum and sent her home.
Slight fever throughout the day ranging from 98.7 to 100.6 (was fluctuating).  Body aches and slight headache.  Taking Tylenol seems to help.
cough which is pneumonia; Head ache; aches and pains; swollen throat; aching teeth; swollen glands; hoarse voice; a feeling of body heaviness; runny nose; This is a spontaneous report from a contactable consumer (patient). A 57-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection; lot number FF2588 and expiry date not reported), via an unspecified route of administration, administered in Arm Right, on 29Sep2021 17:15 (at the age of 57-year-old), as dose 1, single, for COVID-19 immunisation in pharmacy or drug store. Medical history included diabetes, asthma, psoriasis, and COVID-19. The patient previously received pneumococcal vaccine and experienced allergy. Concomitant medications included metformin; dapagliflozin propanediol monohydrate (FARXIGA); berberine; thioctic acid (ALFA LIPOIC ACID). No other vaccine in four weeks prior to COVID vaccine. Patient was not tested for COVID post vaccination. The patient experienced headache, aches and pains, swollen throat, aching teeth, swollen glands, hoarse voice, cough which was pneumonia, a feeling of body heaviness and runny nose on 30Sep2021 07:15. The events resulted in doctor or other healthcare professional office/clinic visit. Patient was treated with antibiotics and OTC remedies. The outcome of the events was not recovered.  No follow-up attempts are needed. No further information is expected.
Redness, rash and slight swelling at the injection site.  Still there a week after the injection.; Redness, rash and slight swelling at the injection site.  Still there a week after the injection.; Redness, rash and slight swelling at the injection site.  Still there a week after the injection.; This is a spontaneous report from a contactable consumer (patient). A 80-year-old male consumer received second dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Lot Number: EN6202, Expiry Date: Unknown), via an unspecified route of administration on left arm on 27Feb2021 at 02:15 PM, at single dose for COVID-19 immunization at Hospital. The patient medical history included Cancer, pneumonia, flu, COPD on an unspecified date and had no Known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19 . The Patient previously received first dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Lot Number: EM9809), via an unspecified route of administration on left arm on 06Feb2021 at 04:45 PM, at single dose for COVID-19 immunization. Patient received other unspecified medications in two weeks, all from an unspecified date and unknown if ongoing. patient has not received any other vaccines within 4 weeks prior to the COVID vaccine. On 01Mar2021, Patient experienced, Redness, rash and slight swelling at the injection site. Still there a week after the injection. patient did not receive any treatment for events. Outcome of all the events was not recovered.  No follow-up attempts are possible. No further information is expected.
Mouth Ulcers on hard palate  some soft palate hard to swallow. . Ulcers were  round lined up in a row. 25 days later woke up with open ulcers on left facial cheek. Round in size lined up in a row three together two below.  Culture  taken was negative for bacteria. I still have some light scaring on face.
Nausea, chills, vomiting, achiness, headache, early onset menses
I am experiencing numbness in my left leg and food.  When walking my left food feels heavy and I can't control my step, i.e., my foot hit the ground with a thud and I can't control it.  It makes waking at a normal pace more difficult and I don't have control nor dexterity that I have in my right leg and foot.
On 10/19/2001 the patient developed flu like symptoms which gradually worsened. The patient complained of chills, hot and cold, cough, red and sore upper palate and throat, sore tongue, sore joints and loss of appetite. The patient was treated with Xylocaine gel, Swish and Swallow, and Tylenol.
Fever & chills (treated with acetaminophen) Arthralgia (shoulders, knees, cervical spine) Headache, moderate pain All symptoms duration: approximately 36-48 hours to complete resolution
pt recvd vax;hives, swollen joints, short of breath;to er;given epi & dph;on 7mar94, same events & went toer again;given IM steroids & prescription for 10 day dose; resolved
second dose of the Moderna vaccine has been administered 2 weeks after the first one/Vaccine received 2 weeks apart; This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose of the Moderna vaccine has been administered 2 weeks after the first one/Vaccine received 2 weeks apart) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 08-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose of the Moderna vaccine has been administered 2 weeks after the first one/Vaccine received 2 weeks apart). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose of the Moderna vaccine has been administered 2 weeks after the first one/Vaccine received 2 weeks apart) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment medications were provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 23-Jun-2021: Follow up received on 23-jun-2021 contains No Significant information. Consent Follow up Declined.
High fevers (102.8 F); localized erythema right deltoid with lymphangitis and cellulitis.  Came to clinic 3/3/08 and was sent directly to ED where she was kept overnight on Vancomycin and released home the next morning on P.O. antibiotics.  T.C. to patient 3/6/08 "feeling fine.  Just a little tired."
Exceeded the 42 day limit of spacing, first shot was received on 04/23/2021.
vertigo; This spontaneous case was reported by a consumer and describes the occurrence of VERTIGO in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VERTIGO. At the time of the report, VERTIGO outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.      No concomitant medications were reported.  Treatment information was not provided.
Bruising and pain at palm up to mid-arm. Swollen arm.  24 hours Fever and chills.  4 hours
I never constituted the HIB vaccination prior to giving, I only administered the saline dilutent.
This spontaneous report as received from a Registered Nurse refers to a male adult patient of unknown age. The patient was administered a 0.5ml pediatric dose of VAQTA (25/0.5 U/ml) injection (lot# unspecified), route and location unspecified on 06-JUL-2012 respectively instead of an adult dose. No adverse events were reported. This is one of several reports received from the same reporter. Additional information is not expected.
This spontaneous report was received from a registered nurse and refers to an unspecified number patients of unknown age and gender. On an unknown date, the patients were vaccinated with an unspecified number of doses of VARIVAX lot # N015477 and expiration date: 18-MAY-2019 (dose, frequency, route of administration were not reported) for prophylaxis, reconstituted with sterile diluent. There were no adverse effects reported. Administered doses of vaccine experienced the temperature excursion from 6 to 14 degrees Fahrenheit for 4 hours. There were previous excursions reported, from 6 to 14 degrees Fahrenheit for 6 hours. Data logger was involved. Sterile diluent used for reconstitution did not undergo a temperature excursion. This is one of two reports received from the same reporter.; Sender's Comments: US-009507513-1708USA011152: